ALLMedicine™ Ankylosing Spondylitis Center

Feb 24th, 2021 - The authors describe the case of a 25-year-old male who presented with a cilioretinal artery occlusion secondary to posterior scleritis. The patient had a history of juvenile spondyloarthritis that evolved into ankylosing spondylitis. Cilioretinal...

Feb 23rd, 2021 - A retrospective study. The aim of this study was to make a thorough comparison of clinical and radiographic outcomes between ankylosing spondylitis (AS) patients with severe kyphosis who underwent one- or two-level pedicle subtraction osteotomy (P...

Feb 21st, 2021 - The aim of this study was to compare the symptoms, treatment patterns, and quality of life (QoL) of ankylosing spondylitis (AS) patients to non-radiographic axial spondyloarthritis (nr-axSpA) patients in the USA. A cross-sectional survey was condu...

Feb 21st, 2021 - Osteoarthritis (OA) is the most prevalent form of arthritis and the major cause of disability and overall diminution of quality of life in the elderly population. Currently there is no cure for OA, partly due to the large gaps in our understanding...

Feb 20th, 2021 - Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease which mainly affects the spine, sacroiliac joint and peripheral joints. To date, the exact causes and pathogenesis of AS still remain unknown. It is considered that the patho...

Sep 30th, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). ankylosing spondylitis

Aug 22nd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Jul 23rd, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthr...

Apr 28th, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthri...

Jul 31st, 2017 - This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid a.

Feb 24th, 2021 - The authors describe the case of a 25-year-old male who presented with a cilioretinal artery occlusion secondary to posterior scleritis. The patient had a history of juvenile spondyloarthritis that evolved into ankylosing spondylitis. Cilioretinal...

Feb 23rd, 2021 - A retrospective study. The aim of this study was to make a thorough comparison of clinical and radiographic outcomes between ankylosing spondylitis (AS) patients with severe kyphosis who underwent one- or two-level pedicle subtraction osteotomy (P...

Feb 22nd, 2021 - Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac. Use the lowest effective dose for the shortest duration consistent with individual pati...

Feb 21st, 2021 - The aim of this study was to compare the symptoms, treatment patterns, and quality of life (QoL) of ankylosing spondylitis (AS) patients to non-radiographic axial spondyloarthritis (nr-axSpA) patients in the USA. A cross-sectional survey was condu...

Feb 21st, 2021 - Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: rheumatoid arthritis osteoarthritis ankylosing spondylitis Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium ta...

Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...

Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...

Jul 1st, 2020 - The age of onset of AS is usually from the late teens to 40 years. Onset in persons older than 50 years is unusual, although diagnosis of mild or asymptomatic disease may be made at a later age. Insidious onset of low back pain is the most common ...

Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...

Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...